Patents by Inventor Tan A. Ince

Tan A. Ince has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11530385
    Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.
    Type: Grant
    Filed: August 1, 2017
    Date of Patent: December 20, 2022
    Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's Hospital, Inc.
    Inventors: Tan A. Ince, Robert A. Weinberg
  • Patent number: 11332712
    Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: May 17, 2022
    Assignee: UNIVERSITY OF MIAMI
    Inventor: Tan Ince
  • Publication number: 20220016135
    Abstract: The invention provides a classification and treatment system for breast cancer using measurements of and ligands for estrogen receptor, androgen receptor, vitamin D receptor, and optionally HER2 receptor.
    Type: Application
    Filed: July 16, 2020
    Publication date: January 20, 2022
    Inventor: Tan Ince
  • Publication number: 20200040301
    Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.
    Type: Application
    Filed: October 10, 2019
    Publication date: February 6, 2020
    Inventor: Tan Ince
  • Patent number: 10465166
    Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: November 5, 2019
    Assignee: UNIVERSITY OF MIAMI
    Inventor: Tan Ince
  • Publication number: 20190071634
    Abstract: Described herein are cell culture media, kits and methods for preparing cell culture media, and methods for culturing cells, for example, cells of the female reproductive tract, and tumor cells.
    Type: Application
    Filed: August 7, 2018
    Publication date: March 7, 2019
    Inventor: Tan A. INCE
  • Publication number: 20180282691
    Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.
    Type: Application
    Filed: August 1, 2017
    Publication date: October 4, 2018
    Inventors: Tan A. Ince, Robert A. Weinberg
  • Publication number: 20180155687
    Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.
    Type: Application
    Filed: July 10, 2017
    Publication date: June 7, 2018
    Inventors: Tan A. Ince, Robert A. Weinberg
  • Publication number: 20170349878
    Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.
    Type: Application
    Filed: August 25, 2017
    Publication date: December 7, 2017
    Applicant: UNIVERSITY OF MIAMI
    Inventor: Tan Ince
  • Patent number: 9777256
    Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: October 3, 2017
    Assignee: UNIVERSITY OF MIAMI
    Inventor: Tan A. Ince
  • Patent number: 9696313
    Abstract: In some aspects, the invention relates to Heat Shock Protein-1 (HSF1) gene and HSF1 gene products. In some aspects, the invention provides methods of tumor diagnosis, prognosis, treatment-specific prediction, or treatment selection, the methods comprising assessing the level of HSF1 expression or HSF1 activation in a sample obtained from the tumor. In some aspects, the invention relates to the discovery that increased HSF1 expression and increased HSF1 activation correlate with poor outcome in cancer, e.g., breast cancer.
    Type: Grant
    Filed: October 5, 2012
    Date of Patent: July 4, 2017
    Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's Hospital, Inc.
    Inventors: Sandro Santagata, Susan Lindquist, Luke J. Whitesell, Tan A. Ince
  • Patent number: 9683217
    Abstract: We describe cell culture media for in vitro culture of a human cancer cell of the lymphocyte lineage (e.g., leukemia, lymphoma, or other blasts) or a precursor thereof, especially T-cell acute lymphoblastic leukemia lymphoma (T-ALL), as well as methods for at least maintenance, propagation, or both of the human cancer cell or its precursor.
    Type: Grant
    Filed: April 12, 2013
    Date of Patent: June 20, 2017
    Assignees: UNIVERSITY OF MIAMI, The Brigham and Women's Hospital, Inc.
    Inventors: Tan A. Ince, Jon C. Aster
  • Publication number: 20170058259
    Abstract: A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors.
    Type: Application
    Filed: September 24, 2014
    Publication date: March 2, 2017
    Inventor: Tan A. Ince
  • Publication number: 20160319239
    Abstract: Described herein are cell culture media, kits and methods for preparing cell culture media, and methods for culturing cells, for example, cells of the female reproductive tract, and tumor cells.
    Type: Application
    Filed: May 5, 2016
    Publication date: November 3, 2016
    Inventor: Tan A. Ince
  • Publication number: 20160146819
    Abstract: A novel classification system for breast cancer based on normal breast cell phenotypes and various expression levels of estrogen receptor (ER), androgen receptor (AR), and vitamin D receptor (VDR). The various categories of the classification system are associated with different survival rates and prognoses. The invention includes a method of classifying breast cancer comprises measuring the levels of ER, AR, and VDR in the cancerous tissue, and classifying the breast cancer into one of the above-noted categories according to expression levels. The invention includes a method of predicting the prognosis of breast cancer in a patient and a method of determining a treatment regimen for breast cancer depending on the category in which the breast cancer is classified. The invention includes a method of treating breast cancer according to the expression profile of ER, AR, and VDR detected in the cancerous tissue. Kits for detecting the same are also provided.
    Type: Application
    Filed: June 19, 2014
    Publication date: May 26, 2016
    Applicant: University of Miami
    Inventor: Tan A. Ince
  • Publication number: 20160102365
    Abstract: Described herein are assays, methods and kits for analyzing sensitivity of a subject's cancerous tumor to a drug, predicting responses of cancerous tumors to drugs, determining the prognosis of a subject having a cancerous tumor, and developing a personalized therapy or treatment strategy for the subject. The assays, methods and kits involve analyzing gene and protein expression signatures or profiles of a subject's cancerous tumor, testing candidate drugs in cancerous cells from the subject's cancerous tumor, and classifying a subject's cancerous tumor based on ovarian cell and fallopian tube cell cell-of-origin gene expression signatures. Using these methods, a suitable drug (or drugs) is identified, the subject can be treated with that drug, and a personalized therapy can be developed for the subject.
    Type: Application
    Filed: June 4, 2014
    Publication date: April 14, 2016
    Inventor: Tan A. Ince
  • Publication number: 20150259644
    Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.
    Type: Application
    Filed: December 15, 2014
    Publication date: September 17, 2015
    Inventors: Tan A. Ince, Robert A. Weinberg
  • Publication number: 20150119557
    Abstract: We describe cell culture media for in vitro culture of a human cancer cell of the lymphocyte lineage (e.g., leukemia, lymphoma, or other blasts) or a precursor thereof, especially T-cell acute lymphoblastic leukemia lymphoma (T-ALL), as well as methods for at least maintenance, propagation, or both of the human cancer cell or its precursor.
    Type: Application
    Filed: April 12, 2013
    Publication date: April 30, 2015
    Applicants: THE UNIVERSITY OF MIAMI, THE BRITISH COLUMBIA CANCER AGENCY BRANCH, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Andrew P. Weng, Jon C. Aster, Tan A. Ince
  • Patent number: 8936939
    Abstract: The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate. The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.
    Type: Grant
    Filed: July 23, 2012
    Date of Patent: January 20, 2015
    Assignees: Whitehead Institute for Biomedical Research, The Brigham and Women's Hospital, Inc.
    Inventors: Tan A. Ince, Robert A. Weinberg
  • Patent number: 8912156
    Abstract: The invention provides methods of targeting tumor stem cells that comprise inhibiting the level and/or activity of HDAC1, HDAC7 and phosphorylated HDAC7. The invention further provides methods for identifying tumor stem cells comprising detecting increased levels and/or activity of HDAC1, HDAC7 and phosphorylated HDAC7. Further provided are kits and articles of manufacture comprising inhibitors of the level and/or activity of HDAC1, HDAC7 and phosphorylated HDAC7. Methods for screening for inhibitors of the level and/or activity of HDAC1, HDAC7 and phosphorylated HDAC7 are also provided.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: December 16, 2014
    Assignee: Whitehead Institute for Biomedical Research
    Inventors: Tan A. Ince, Tong Ihn Lee, Richard A. Young